Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × cabozantinib × Clear all
NCT02260531 2021-05-20

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Completed
36 enrolled 19 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡